Jun. 25 at 7:35 PM
$SPRY The problem isn't with Neffy. The problem is management lacks any industry power. They are nobodies. One trick ponies. Still learning. Viatris, one of the most powerful bios on the planet, is continuing to steer SPRY's ship. VTRS already, was single handedly responsible for Neffy getting the CRL way back when. They are also responsible for the slow, turtle pace uptake of Neffy. VTRS without any doubt, simply made a phone call, filled up some bank accounts and now CVS 'delayed' them til 2027. It's not over. VTRS will continue to protect their 9 figure revenue stream and throw every wrench into every gear SPRY has turning.
If I was leading VTRS, I'd go full retard and pay off every entity, every doctor, everything, to keep Neffy at bay. For as long as possible. But once Anaphylm hits the market early 2027, VTRS will now have to fight 2 products and AQST is far more powerful than SPRY. It's possible VTRS then stars putting the wrenches back into the toolboxes.
